Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Amortizatization of Intangibles: 2014-2025

Historic Amortizatization of Intangibles for Viking Therapeutics (VKTX) over the last 10 years, with Sep 2025 value amounting to $2.0 million.

  • Viking Therapeutics' Amortizatization of Intangibles fell 59.25% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 27.32%. This contributed to the annual value of $17.3 million for FY2024, which is 110.52% up from last year.
  • As of Q3 2025, Viking Therapeutics' Amortizatization of Intangibles stood at $2.0 million, which was down 15.14% from $2.4 million recorded in Q2 2025.
  • Viking Therapeutics' 5-year Amortizatization of Intangibles high stood at $5.4 million for Q2 2024, and its period low was -$1.1 million during Q1 2021.
  • Over the past 3 years, Viking Therapeutics' median Amortizatization of Intangibles value was $2.8 million (recorded in 2024), while the average stood at $3.0 million.
  • Per our database at Business Quant, Viking Therapeutics' Amortizatization of Intangibles crashed by 111.84% in 2021 and then soared by 4,998.11% in 2023.
  • Over the past 5 years, Viking Therapeutics' Amortizatization of Intangibles (Quarterly) stood at -$755,000 in 2021, then surged by 107.02% to $53,000 in 2022, then spiked by 4,998.11% to $2.7 million in 2023, then surged by 49.19% to $4.0 million in 2024, then plummeted by 59.25% to $2.0 million in 2025.
  • Its Amortizatization of Intangibles stands at $2.0 million for Q3 2025, versus $2.4 million for Q2 2025 and $3.1 million for Q1 2025.